Dec 7, 2022
Global Antibody Drug Conjugates Contract Manufacturing Market, By Condition (MyelomaLymphoma, Breast Cancer, Others (Urothelial Cancer), Lin
seen from United States
seen from China
seen from T1
seen from United States
seen from Türkiye
seen from Spain
seen from China
seen from United States
seen from United States
seen from Kenya
seen from United States
seen from United States
seen from T1
seen from United States
seen from Brazil
seen from Argentina
seen from United States
seen from Türkiye
seen from Türkiye
seen from United States
Global Antibody Drug Conjugates Contract Manufacturing Market, By Condition (MyelomaLymphoma, Breast Cancer, Others (Urothelial Cancer), Lin
Global Antibody Drug Conjugates Contract Manufacturing Market, By Condition (MyelomaLymphoma, Breast Cancer, Others (Urothelial Cancer), Lin
Data Bridge Market Research analyses that the antibody drug conjugates contract manufacturing market which was USD 8.2 billion in 2021, would rocket up to USD 12.35 billion by 2029, and is expected to undergo a CAGR of 5.25% during the forecast period 2022 to 2029.
Roots Analysis
Roots Analysis offers market research reports highlighting insightful opinions within the pharma, biotech and medical devices industry. With over 500 clients spread across the small pharma, large pharma, VC firms and academic institutes, our intellectual capital encompasses very niche / emerging market segments.
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
The porphyria therapies market is projected to grow at an annualized rate of 10.97% during the period 2021-2030, claims Roots Analysis
Several novel and innovative therapeutic approaches, both small molecule and biologics, are being currently investigated at various phases of development in order to avoid the beginning of disease-induced attacks and other long-term effects of porphyria
Roots Analysis has announced the addition of “Porphyria Targeting Therapies Market, 2021-2030” report to its list of offerings.
Porphyria is a rare disorder that is characterized by excessive accumulation of porphyrin, a compound that aids in the formation of heme (an essential part of hemoglobin that helps carry oxygen in blood). Any anomaly caused by genetic or acquired abnormalities in heme biosynthesis (produced majorly in bone marrow and liver) can result in toxicity. It is worth highlighting that, till date, more than 1,000 mutations that can cause porphyria have been identified. However, prevalence of porphyria still remains unknown. Several treatment options such as gene therapy, proteasome inhibition and pharmacologic chaperones are currently being investigated among various other targeted treatment options.
To order this 130+ slides report, which features 90+ figures, please visit https://www.rootsanalysis.com/reports/porphyria-pipline-review.html.
Key Market Insights
15+ therapies have been / are being developed for the treatment of different types of porphyria
More than 70% of the aforementioned candidates are currently under clinical evaluation. Further, three therapies, namely Panhematin™, GIVLAARI® and SCENESSE®, have already been approved for the treatment of different types of porphyria.
Around 50% of the therapeutics are being developed as biologics
Majority (over 65%) of the abovementioned biologic drugs have been / are being designed for administration via the intravenous route. Furthermore, majority of the drugs (37%) have been / are being targeting acute intermittent porphyria.
Over 30% of the therapies have been / are being developed for erythropoietic protoporphyria
More than 65% the abovementioned therapies are currently being evaluated in clinical phases. Further, around 60% of the aforementioned therapy candidates are being developed as small molecules.
More than 45% of the players evaluating therapies for porphyria are small companies
North America has emerged as a key hub for the development of porphyria therapies, featuring the presence of 65% developers. The developer landscape is further dominated by players that have been established between 2001-2010, representing around 45% of the total number of stakeholders.
A number of clinical trials evaluating therapies for porphyria, have been registered
Majority of the clinical studies have been completed. More than 30% of the overall trials are phase I studies. Further, it is worth noting that, most of the trials (~ 60%) focused on porphyria therapies were registered post-2010.
Partnership activity in this field has increased at a CAGR of 9.6%, between 2018 and 2020
More than 70% of the reported deals were established post-2018, with the maximum activity being reported in 2019 and 2020. Majority of the instances captured in the report were product distribution / commercialization agreements (~45%).
380+ articles have been published related to porphyria, since January 2018
Close to 20% publications mentioned in the report were focused on the assessment of therapeutics that have been / are being developed for the treatment of erythropoietic protoporphyria. Example of prominent journals include (in decreasing order of number of publications) Molecular Genetics, Orphanet Journal of Rare Diseases, British Journal of Dermatology and Molecular Genetics, and Metabolism Reports.
Around 15 eminent individuals were identified as key opinion leaders (KOLs) in this domain
More than 65% of these KOLs were observed to be associated with organizations based in US, followed by those affiliated to institutes in Spain (20%) and South Africa (7%). Further, over 65% of the KOLs are currently affiliated to academic institutes, such as schools and universities.
North America is anticipated to capture over 60% of the global market share in 2030
In 2030, more than 50% of the market revenues are expected to be generated from sales of therapeutics intended for the treatment of erythropoietic protoporphyria and porphyria cutanea tarda. Further, therapies designed for oral route of administration are expected to occupy a larger share (51%) of the overall market, in the foreseen future.
To request a sample copy / brochure of this report, please visit this link.
Key Questions Answered
§ What are the prevalent R&D trends related to Porphyria?
§ What are the key challenges faced by stakeholders engaged in this domain?
§ What are the principal therapies developed by the companies in this domain?
§ Who are the leading industry and non-industry players in this market?
§ What are the key geographies where research on porphyria is actively being conducted?
§ Who are the key investors in this domain?
§ Who are the key opinion leaders / experts in this field?
§ What kind of partnership models are commonly adopted by industry stakeholders?
§ What are the factors that are likely to influence the evolution of this upcoming market?
§ How is the current and future market opportunity likely to be distributed across key market segments?
The financial opportunity within the porphyria therapies market has been analyzed across the following segments:
§ Drug
§ GIVLAARI®
§ Panhematin®
§ SCENESSE®
§ MT-7117
§ Colestid
§ HARVONI®
§ Type of Porphyria
Acute Hepatic Porphyria
Acute Intermittent Porphyria
Erythropoietic Protoporphyria
Hereditary Coproporphyria
Porphyria Cutanea Tarda
Variegate Porphyria
X-Linked Porphyria
§ Route of Administration
Oral
Intravenous
Subcutaneous
§ Key Geographical Regions
North America
Europe
Asia-Pacific
The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.
§ Agios Pharmaceutical
§ Alnylam Pharmaceuticals
§ Clinuvel Pharmaceuticals
§ Disc Medicine
§ Mitsubishi Tanabe Pharma
§ Moderna Therapeutics
§ Palatin Technologies
§ Recordati Rare Diseases
For additional details, please visit https://www.rootsanalysis.com/reports/porphyria-pipline-review.html or email [email protected]
You may also be interested in the following titles:
1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
2. Soft Tissue Sarcoma: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
The Site Management Organizations (SMO) Market is Anticipated to Grow at a CAGR of 9.8%, Currently, around 245 industry players are...
Innovators in the pharmaceutical industry are constantly developing ways to improve the process of conducting clinical trials and managing research sites. Amidst other alternatives, outsourcing various trial operations to a specialized service provider, such as site management organizations (SMOs), has emerged as a viable option for various developers. The advantages of engaging such specialized service providers are numerous and enable sponsors to meet their clinical research timelines. In addition, SMOs can facilitate rapid patient recruitment, reduce study timelines, and manage the entire clinical trial processes and administrative work for their clients. Moreover, drug / medical device developers, and even the contract research organizations (CROs), can employ the therapeutic and operational expertise, global site networks and well-established processes and tools offered by SMOs in order to carry out their clinical research and site management activities in a cost and time-efficient manner.
Our Social Media Platform
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
Regulatory T-cell Therapies (Tregs) are a mature subpopulation of T-cells that play a critical role in mediating immunological...
The Regulatory T-Cell Therapies (Tregs) are a mature subpopulation of T-cells that play a critical role in mediating immunological tolerance to self-antigens and suppress immune responses that are harmful to the host, thereby, enabling homeostasis. These mainly develop in thymus from CD4+ thymocytes and are mainly of three types: natural Tregs, adaptive Tregs and invitro Tregs. Tregs can either be directly administered or can be transduced with T cell receptor (TCR) or chimeric antigen receptor (CAR) which have high affinity to target antigens. In recent years, Treg based therapies have become a research hotspot in the field of immunotherapy due to their ability to prevent / delay graft rejection and control autoimmune responses generated post adoptive transfer in vivo.
Our Social Media Platform
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
Owing to the recent developments in the field of myeloid cell targeting therapies, they can be considered as the potential alternatives..
The global cancer burden is increasing rapidly with over 19 million new cancer cases and 10 million deaths reported in the year 2020. Given the rising prevalence, researchers have made significant efforts in discovering new approaches for the treatment of oncological diseases. With several programs having entered the clinical stages, myeloid cell targeting therapies have emerged as a novel strategy in the suite of cancer immunotherapy approaches.
All the blood and immune cells are formed from the hematopoietic stem cell, with multiple stepwise intermediates. The hematopoietic hierarchy is divided into two primary branches: the myeloid cells and lymphoid cells.
Our Social Media Platform
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/
The progressive supranuclear palsy (PSP) therapies market, is projected to grow at a CAGR of over 35% in the coming decade, predicts Roots Analysis
The exact cause of this rare disorder, which affects 5-17 in 100,000 people, is unknown; however, a complex interplay between different risk factors, including age, genetics and environment, is likely to contribute to the onset of this rare tauopathy
Roots Analysis is pleased to announce the publication of its recent study, titled, “Progressive Supranuclear Palsy Therapies Market, 2021-2030”
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
§ A detailed assessment of the therapeutic pipeline activity and therapeutic assessment of the products.
§ Detailed profiles of the players that are engaged in the development of drug products / therapies for progressive supranuclear palsy.
§ A detailed analysis of completed, ongoing and planned clinical studies, based on the various relevant parameters.
§ A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs.
§ An in-depth analysis of grants awarded to various research institutes for the projects related to progressive supranuclear palsy, in the period between 2010 and July 2021.
§ An in-depth analysis of the published articles related to PSP and potential therapeutics based on the year of publication, top authors, key journals and emerging focus areas.
§ An analysis of the partnerships that have been inked by stakeholders in this domain since 2015, covering instances of research and development, licensing, product development, clinical trials, and other relevant types of deals.
§ An insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules (phase II), taking into consideration target patient population, expected launch date, competitive landscape, annual treatment cost and likely adoption of the therapy.
§ A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
§ Phase II Drugs
§ AZP2006
§ RT001
§ BRAVYL
§ Emeramide
§ NORTHERA
§ Type of Therapy
§ Curative
§ Symptomatic / Palliative
§ Regional Distribution
§ North America (US)
§ Europe (France, Germany, Italy, Spain, UK)
The report also features detailed transcripts of discussions (in reverse chronological order) held with the following experts:
§ Daniel Brennan (Business and Operations Advisor, NeuroTau)
§ Fabrizio Stocchi (Director of the Parkinson’s Disease and Movement Disorders Research Center, IRCCS San Raffaele)
Key companies covered in the report
§ Alzprotect
§ Retrotope
§ Woolsey Pharmaceuticals
§ EmeraMed
§ Lundbeck
§ NeuroTau
For more information please click on the following link:
https://www.rootsanalysis.com/reports/progressive-supranuclear-palsy-market.html
Other Recent Offerings
1. Brain Concussion Market, 2021-2031
2. Hunter Syndrome: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
3. Pediatric Brain Tumors: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
4. Neurotrophic Keratitis: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
5. Neuromyelitis Optica Spectrum Disorder (2nd Edition): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact Details
Ben Johnson
+1 (415) 800 3415
Roots Analysis
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis.com
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/